ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
A. Sowmiya1, Santhoshkumar Jayakodi1, K.A. Selvam2 and K. Sangeetha1
1Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, India.
2Department of Microbiology, Indo-American College, Cheyyar, Thiruvannamalai, Tamil Nadu, India.
Article Number: 9470 | © The Author(s). 2024
J Pure Appl Microbiol. 2024;18(3):1674-1683. https://doi.org/10.22207/JPAM.18.3.16
Received: 05 April 2024 | Accepted: 20 June 2024 | Published online: 22 July 2024
Issue online: September 2024
Abstract

Targeting the class A Beta lactamases Omega loop is an ideal way to combat drug resistance because of its significant role in the catalytic activity and deacylation process inhibition. Therefore, the molecular docking approach with computerized peptide-based in silico screening has been applied for the identification of inhibitors of TEM-type βLs. Among the subjected 105 peptides, Chrombacin (-47.8 KJ/mol), Gassericin A (-35.7 KJ/mol), Duramycin (-34.1 KJ/mol), Brevinin-1DYa (-34.0 KJ/mol), Amoebapore A (-31.2 KJ/mol), Mundticin ATO6 (-29.0 KJ/mol), Lactocyclicin Q (-26.3 KJ/mol), Cinnamycin (-25.9 KJ/mol showed highest binding energy. Among the peptides that showed the highest docking score Elafin, Cinnamycin, Duramycin interacted with Lys 73 of the α domain of catalytic residues of TEM-1 Beta lactamases, whereas Taromycin A, Gassericin A interacted with Lys 234 of the β domain, depicting a strong inhibition and also exhibited desirable physicochemical properties. Hence further in vitro examination of these cyclic peptides against the resistant strains is warranted to help design further novel inhibitors based on their scaffolds and also for the development of an effective drug combination regime.

Keywords

Cyclic Peptides, Protein-Peptide Docking, Allergenicity, Toxicity, TEM-1 Beta-lactamases

Article Metrics

Article View: 930

Share This Article

© The Author(s) 2024. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.